Colesevelam - Ironwood Pharmaceuticals

Drug Profile

Colesevelam - Ironwood Pharmaceuticals

Alternative Names: IW-3718

Latest Information Update: 27 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Amines; Antihyperglycaemics; Antihyperlipidaemics; Digestion aids; Polymers
  • Mechanism of Action Bile acid binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastro-oesophageal reflux

Most Recent Events

  • 27 Jun 2018 Ironwood Pharmaceuticals initiates enrolment in a phase III trial for Gastro-oesophageal reflux in USA (PO) (NCT03561090)
  • 21 Jun 2018 Phase-III clinical trials in Gastro-oesophageal reflux in USA (PO) (NCT03561883)
  • 21 Jun 2018 Ironwood Pharmaceuticals plans a regulatory filing with the US FDA in USA for Gastro-oesophageal reflux
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top